The phase 2a trial showed GR-0621 met primary and secondary endpoints, demonstrating safety and efficacy over 12 weeks. Phase 2a data show oral GRI-0621 was safe and improved immune and fibrosis ...

Antifibrotic therapy shows similar efficacy in familial and sporadic IPF, with no significant differences in survival or acute exacerbations. Because familial idiopathic pulmonary fibrosis is ...

Designation highlights significant unmet medical needAUSTIN, Texas, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ...

Boehringer Ingelheim announced the start of a Phase IIa clinical trial evaluating BI 765423, a novel monoclonal antibody targeting interleukin-11 (IL-11), in patients with idiopathic pulmonary ...

Competitive powerlifting lives and dies on small details. A lift that looks good in the gym can turn into a red light on the ...

What’s more, he explained, several groups have examined existing databases (e.g. Optum, prior clinical trials in IPF, registries) and suggested that metformin therapy in people wiht diabetes with IPF ...

Brainomix, a global leader and pioneer of AI-powered imaging tools in lung fibrosis and stroke, today announced it was ...

Boehringer Ingelheim begins phase IIa trial of BI 765423, a novel monoclonal antibody targeting IL-11, in patients with idiopathic pulmonary fibrosis: Ingelheim, Germany Thursday, ...

The BIM-IOL is designed to be implanted during cataract surgery, tackling IOP while restoring vision, and SpyGlass is also ...

Detailed price information for Tvardi Therapeutics Inc (TVRD-Q) from The Globe and Mail including charting and trades.

Wheelchair users in Northern Ireland are being invited to join The Wheelchair Collective – the first national council of ...

Cereno Scientific , an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced the publication of the first peer ...